Immune myopathies with perimysial pathology (IMPP)
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Immune myopathies with perimysial pathology (IMPP). Females are predominantly affected. Fully referenced neurology checklist.
Demographic features
- Females are predominantly affected
- The mean onset age is 47 years
Myopathic features
Locked: subscribe to see this section.
Systemic features
Locked: subscribe to see this section.
Investigations
Locked: subscribe to see this section.
Differential diagnosis
Locked: subscribe to see this section.
Pathology
Locked: subscribe to see this section.
Acute treatment
Locked: subscribe to see this section.
Long-term immunosuppression
Locked: subscribe to see this section.
References
- Bucelli RC, Pestronk A. Immune myopathies with perimysial pathology: Clinical and laboratory features. Neurol Neuroimmunol Neuroinflamm 2018; 5:e434.
- Kwon PM, Zhou L, Motiwala R, Kerr LD, Shin SC. Immune myopathy with perimysial pathology associated with interstitial lung disease and anti-EJ antibodies. J Clin Neuromuscul Dis 2017; 18:223-227.
- Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. JNNP 2009; 80:904-908.
- Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015; 2:e124.
